Contraindicated (one)bortezomib will improve the amount or effect of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Sturdy or reasonable CYP2C19 inhibitors may perhaps boost mavacamten systemic publicity, causing coronary heart failure as a result of systolic dysfunction. chloramphenicol will increase the stage or impact of bortezomib by influencing hepati... https://juliuswhscn.blogsuperapp.com/27246997/top-guidelines-of-imidacloprid